ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting...
Paragon 28® was well represented at American College of Foot and Ankle Surgeons (ACFAS) Meeting on February 11th-14th. Management, sales representatives and engineers from Paragon 28 were on-hand to demonstrate and exhibit our multiple product lines to the thousands of foot and ankle surgeons in attendance. A Paragon 28 hosted event took place on Friday, February...
The name “Paragon 28” was chosen by design — to never lose focus on our goal to advance the science of foot and ankle surgery.
© 2024 Paragon 28, Inc.
